Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children
NCT: NCT06929702 · RECRUITING
広告
NCT識別子NCT06929702
ステータスRECRUITING
開始日2025-07-09
完了2027-10-01
SponsorUniversity Hospital, Ghent (OTHER)
First posted
Last updated
概要
The overall objective of this study is to investigate the impact of early model-informed precision dosing (MIPD) on target attainment of three beta-lactam antibiotics (amoxicillin-clavulanic acid, piperacillin-tazobactam and meropenem) in critically ill children. This evaluation includes a comparison with the more standard approach on clinical and patient-oriented measures.
公式ソース
ClinicalTrials.govで見る →データはClinicalTrials.gov APIから取得しています。最新のステータスは公式記録をご確認ください。